SLC5A2 and type 2 diabetes mellitus: Although we previously examined the effects of SGLT2 and DPP4 inhibition on endothelial function using flow-mediated dilation in T2DM patients treated with 750 mg metformin [25, 30], we could not compare the effects of SGLT2 and DPP4 inhibition directly and both agents tended to increase the flow-mediated dilation.